Rupal S Bhatt

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Biomarkers for monitoring antiangiogenic therapy
    Rupal S Bhatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:777s-780s. 2007
  2. pmc Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
    R S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MASCO 426, Boston, MA 02215, USA
    Br J Cancer 105:112-7. 2011
  3. pmc Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    Rupal S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 9:2793-802. 2010
  4. pmc A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
    Rupal S Bhatt
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 116:1751-6. 2010
  5. pmc High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Transl Med 9:220. 2011
  6. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
  7. pmc Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
    Liang Zhang
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
    PLoS ONE 6:e19144. 2011
  8. pmc Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
  9. doi request reprint Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
    Rupal S Bhatt
    Division of Cancer Biology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    BJU Int 102:358-63. 2008
  10. doi request reprint The challenge of herbal therapies for prostate cancer
    Rupal S Bhatt
    Cancer Biology and Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7581-2. 2008

Collaborators

Detail Information

Publications10

  1. ncbi request reprint Biomarkers for monitoring antiangiogenic therapy
    Rupal S Bhatt
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, MA 02215, USA
    Clin Cancer Res 13:777s-780s. 2007
    ..Surrogate markers of angiogenesis could help with selecting patients for therapy, determining optimal dosing of therapy, deciding whether to change therapy, and assessing appropriate salvage therapy...
  2. pmc Increased mobilisation of circulating endothelial progenitors in von Hippel-Lindau disease and renal cell carcinoma
    R S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, 375 Longwood Avenue, MASCO 426, Boston, MA 02215, USA
    Br J Cancer 105:112-7. 2011
    ..Because of the highly angiogenic phenotype of renal cell carcinoma (RCC), we sought to assess the potential of CECs as a marker of RCC in patients with von Hippel-Lindau (VHL) disease and those with sporadic RCC...
  3. pmc Renal cancer resistance to antiangiogenic therapy is delayed by restoration of angiostatic signaling
    Rupal S Bhatt
    Division of Hematology Oncology and Cancer Biology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Mol Cancer Ther 9:2793-802. 2010
    ....
  4. pmc A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma
    Rupal S Bhatt
    Division of Hematology and Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
    Cancer 116:1751-6. 2010
    ..Angiogenesis, which is the growth of new blood vessels, is necessary for tumor growth and progression. Thus, the authors tested the safety and efficacy of a low dose of paclitaxel and celecoxib in patients with MM...
  5. pmc High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma
    Xiaoen Wang
    Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    J Transl Med 9:220. 2011
    ..However, resistance to therapy develops at a median of 5 months. In an effort to increase efficacy, we studied the effects of increased sorafenib dose and intermittent scheduling in a murine RCC xenograft model...
  6. ncbi request reprint Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leak
    Diana C Gallagher
    Division of Pulmonary and Critical Care, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 13:2115-20. 2007
    ..However, a major toxicity is vascular leak syndrome (VLS). We previously reported elevated serum angiopoietin 2 (Ang2) in septic patients with vascular leak and hypothesized that Ang2 might also contribute to HDIL2 VLS...
  7. pmc Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression
    Liang Zhang
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States of America
    PLoS ONE 6:e19144. 2011
    ..We examined whether resistance occurs at least in part via reversible, physiologic changes in the tumor, or results solely from stable genetic changes in resistant tumor cells...
  8. pmc Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial
    Robert W Ross
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:4777-84. 2012
    ..Treatment of high-risk localized prostate cancer remains inadequate. The authors performed a phase 2 multicenter trial of neoadjuvant docetaxel plus bevacizumab before radical prostatectomy...
  9. doi request reprint Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor
    Rupal S Bhatt
    Division of Cancer Biology, Beth Israel Deaconess Medical Center, Boston, MA, USA
    BJU Int 102:358-63. 2008
    ....
  10. doi request reprint The challenge of herbal therapies for prostate cancer
    Rupal S Bhatt
    Cancer Biology and Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 14:7581-2. 2008
    ..Identification of the biological effects of herbal remedies such as silibinin is critical for their development as anticancer treatments...